FDA Ramps Up Unannounced Inspections at Foreign Manufacturing Facilities- Here’s How to Prepare

On May 6th, 2025, the FDA released a news release titled “FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities.” In this blog, we will examine the implications of this decision and what manufacturers can do to adapt to this new change. 

Overview of the FDA’s Announcement 

The recent announcement by the FDA signals a significant shift in its oversight approach toward foreign manufacturing facilities. The FDA is expanding its use of unannounced inspections, particularly for facilities that produce foods, medical products, and essential medicines. 

This change, driven by the current administration’s increasing scrutiny of foreign firms, aims to bolster compliance of goods entering the US supply chain to FDA requirements. This new policy marks a notable departure from previous practices that often involved advance notice for facility inspections. 

 This means that FDA investigators can arrive at foreign manufacturing facilities without notice to scrutinize processes, documentation, and adherence to regulatory standards. This approach aims to address concerns about potential data manipulation or substandard practices that might be concealed during scheduled visits. 

Implications for Foreign Manufacturers 

For foreign manufacturing facilities, the implications of this expanded unannounced inspections policy are substantial. Companies operating in regions like India and China, which have historically been subject to scrutiny, must now prepare for more unannounced inspections. According to the GAO, as of January 2024, India had approximately 592 registered drug manufacturing establishments subject to inspection, and China had about 487; we can only assume that these numbers will increase once the new inspection policy is in effect. The new directive may also disproportionately affect firms in their surrounding regions. This shift necessitates a heightened state of readiness, requiring continuous compliance with FDA regulations. Foreign manufacturers must maintain impeccable records, ensure consistent adherence to GMP, and implement robust internal audit programs. The move could affect American companies that rely on outside firms for their raw materials and excipients, with potential disruptions to the supply chain if these firms are found to be non-compliant. 

Strategies for Compliance with New Regulations 

To navigate the complexities of the expanded use of unannounced inspections, companies must adopt proactive strategies to ensure compliance. This includes focusing on several key areas: 

1. Investing in comprehensive training programs for their staff to ensure a thorough understanding of FDA regulations and expectations. 

1. Implementing robust internal audit programs will enable the firms to identify and address potential weaknesses before they are detected by the FDA. 

1. Developing strong relationships with regulatory experts who can provide guidance and support. 

Additionally, companies should embrace technological solutions that streamline data management, improve traceability, and facilitate real-time monitoring of critical processes. Investing in these strategies will not only mitigate the risk of regulatory action but also enhance the overall quality and competitiveness of foreign facilities. 

For US Companies Relying on Foreign Suppliers 

Preparation for Potential Audits 

To mitigate these risks, US companies need to proactively prepare for potential audits of their foreign suppliers. These domestic and foreign firms should conduct thorough due diligence on their suppliers, assessing their compliance with FDA regulations and industry best practices. The companies may want to consider investing in comprehensive supplier qualification programs that include regular audits and assessments of manufacturing processes. The inspections should be thorough and follow FDA guidelines. US companies should also establish clear communication channels with their suppliers, ensuring that they are informed of any regulatory changes or updates. 

Building Stronger Relationships with Suppliers 

Open communication and collaboration can foster a culture of compliance and continuous improvement between manufacturers and suppliers. Sharing best practices, providing training, and offering support to suppliers can help them enhance their manufacturing processes and meet FDA requirements. US companies should also consider entering into long-term contracts with reliable suppliers that have a proven track record of compliance. The increased FDA oversight is an opportunity to strengthen supply chain transparency and accountability. Establishing mutually beneficial partnerships will help ensure a stable and reliable supply of high-quality materials and medicine. 

Navigating the Increased Audits 

Utilizing Technology to Manage Inspection Processes 

Leveraging technology is crucial for effectively managing the complexities of inspection processes, especially with the new unannounced inspections policy. Implementing electronic quality management systems (eQMS) can streamline documentation, track corrective and preventive actions (CAPA), and facilitate real-time monitoring of critical processes. Data analytics tools can help identify trends and potential risks, enabling companies to proactively address issues before they escalate. 

The Role of Internal Audits in Preparation 

Conducting regular internal audits helps companies identify weaknesses in their quality systems, assess compliance with regulatory requirements, and implement corrective actions. The unannounced inspections policy highlights the importance of a robust internal audit program. These audits should be comprehensive, covering all aspects of the manufacturing process, from raw material sourcing to finished product/release. By proactively addressing potential issues, companies can significantly reduce the risk of adverse findings during FDA inspections.  

How PSC Software’s ACE Can Help 

Features of ACE for Compliance Management 

PSC Software’s eQMS, ACE, offers a comprehensive suite of features designed to streamline compliance management and prepare companies for FDA inspections. ACE provides centralized document control, automated workflows for CAPA management, and real-time monitoring of critical quality metrics. The system also includes robust audit management capabilities, allowing companies to schedule, conduct, and track internal audits effectively. Furthermore, ACE integrates with other enterprise systems, providing a holistic view of quality and compliance across the organization.  

Getting More Information on PSC Software’s Solutions 

Ready to strength your compliance strategy? Request a personalized demo of ACE to see how it can be tailored to meet your specific needs.